Peptide TSE Risk Assessment: The Animal Origin Paperwork a COA Does Not Carry

A peptide TSE risk assessment is a documentary control, not an analytical one. No certificate of analysis, however complete its purity, identity and endotoxin sections, can establish whether an amino acid derivative used in the synthesis originated in animal tissue, which species it came from, or which country that animal lived in. That information exists only in supply chain records held several tiers upstream of the laboratory that ran the chromatography.

This is a different category of gap from the ones usually discussed on a purity page. Residual solvents, elemental impurities and truncation sequences are all invisible to a standard reversed phase purity method, but each becomes visible the moment you run the correct orthogonal method. Animal origin is not like that. There is no assay that reveals it after the fact. The control is a paper trail, and if the paper trail was never assembled, the information is simply gone.

Why no analytical method closes this gap

The governing text in Europe is the Note for Guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products, EMEA/410/01 revision 3, published in the Official Journal of the European Union C 73 on 5 March 2011 and reproduced as European Pharmacopoeia general chapter 5.2.8. Its position on testing is unusually blunt for a regulatory document. Readily applicable diagnostic tests for transmissible spongiform encephalopathy infectivity in living animals are not yet available. Diagnosis rests on post mortem confirmation of characteristic brain lesions by histopathology, on detection of the abnormal prion protein by Western blot or immunoassay, or on inoculation of suspect tissue into target species or laboratory animals. Because incubation periods run to months or years, results of the in vivo confirmation arrive long after the material has been consumed.

Several immunochemical tests for the abnormal prion protein in post mortem samples are described in the guideline as extremely sensitive. The guideline then removes the comfort that sentence offers. Their ability to detect an infected animal depends on when the sample was collected relative to exposure, which tissue was collected, and how much infectious material the animal acquired. The conclusion is explicit: none of the tests are considered suitable to unambiguously confirm the negative status of an animal. A negative screening result on a source animal is not a clean bill of health, which is why the entire framework is built on sourcing rules rather than on release testing.

Having ruled out testing as the primary safeguard, the guideline names three complementary parameters that carry the risk instead: the source animals and their geographical origin, the nature of the animal material used in manufacture together with any procedures in place to avoid cross-contamination with higher risk materials, and the production processes including the quality assurance system that ensures product consistency and traceability. Every one of those three lives in a supplier file. None of them lives on a certificate of analysis. The guideline states the reason in a single sentence: controlled sourcing is a very important criterion in achieving acceptable safety of the product, due to the documented resistance of these agents to most inactivation procedures.

What the guideline says about amino acids specifically

Section 6.8 of the guideline deals with amino acids directly, and it opens with a sentence that surprises most people who assume peptide building blocks are purely synthetic chemistry: amino acids can be obtained by hydrolysis of materials from various sources. Unless otherwise justified, the starting material for the manufacture of amino acids shall be Category 3 material or equivalent as defined in Regulation (EC) No 1774/2002, the European animal by-products regulation of 3 October 2002.

The guideline then sets out a specific processing route that is considered unlikely to present a risk. Amino acids produced from hides and skins by a process involving exposure of the material to a pH of 1 to 2, followed by a pH above 11, followed by heat treatment at 140 degrees Celsius for 30 minutes at 3 bar. The resulting amino acids or peptides must be filtered after production. Analysis must be performed using a validated and sensitive method to control any residual intact macromolecules, with an appropriate limit set. Amino acids prepared under other conditions must demonstrate compliance separately.

Read that third condition carefully, because it is the only analytical control in the chain and it is not where a research buyer would look for it. The validated method for residual intact macromolecules is run by the amino acid producer, on the amino acid, at the top of the supply chain. It is not run by the peptide manufacturer, and its result does not propagate onto the finished peptide certificate. By the time a vial of lyophilised material reaches a laboratory in Canada, that control is four or five commercial handoffs behind it: peptide certificate, peptide manufacturer, protected amino acid supplier, amino acid producer, rendering operation, abattoir, herd, country. The certificate sits at one end of that chain and the risk decision was made at the other. The same structural problem applies to every impurity inherited from the building blocks rather than created during assembly, which is covered in more detail in our analysis of the Fmoc amino acid impurities a finished COA cannot reach.

Key Research Findings

• Stainless steel wire segments measuring 0.15 by 5 mm, exposed to scrapie-infected mouse brain homogenate and then washed extensively with phosphate buffered saline, retained the equivalent of roughly 10 to the fifth LD50 units per segment when implanted into indicator mice (Zobeley, Flechsig, Cozzio, Enari and Weissmann, Molecular Medicine, 1999, volume 5, pages 240-243).
• In the same study, exposure to 10 percent formaldehyde for one hour reduced retained infectivity by only about 30-fold, confirming that surface-bound infectivity behaves very differently from infectivity in suspension.
• More than 184,000 cattle in the United Kingdom died of bovine spongiform encephalopathy between 1986 and 2015, across more than 35,000 affected herds, with confirmed cases peaking in 1993 at close to 1,000 new cases each week (US Centers for Disease Control and Prevention, page last reviewed 7 July 2025).
• By 2005 the number of countries reporting the disease in native cattle had reached 24. Canada recorded an imported case in 1993 and 19 further cases beginning in 2003, and six cases have been identified in the United States, of which one was imported and the remainder were atypical.
• EMEA/410/01 revision 3, section 6.8, permits amino acids produced from hides and skins where the material sees pH 1 to 2, then pH above 11, then 140 degrees Celsius for 30 minutes at 3 bar, followed by filtration and a validated method controlling residual intact macromolecules against a set limit.
• The same guideline states that none of the available screening tests are considered suitable to unambiguously confirm the negative status of an animal, which is why sourcing controls rather than release testing carry the risk.
• The World Organisation for Animal Health recognised Canada as a country of negligible risk on 27 May 2021, an upgrade from the controlled risk status Canada had held since May 2007.

Why prions do not behave like the impurities a certificate is built to catch

The Zobeley study is worth dwelling on because it explains why this risk category is handled by paperwork rather than by cleaning records. The group at the University of Zurich modelled contaminated surgical instruments by exposing thin stainless steel wire segments to scrapie agent, washing them exhaustively with or without formaldehyde, then implanting them into the brains of indicator mice and estimating infectivity from the time elapsing to terminal disease. Extensive washing with buffer left roughly 10 to the fifth LD50 units bound to each 0.15 by 5 mm segment. An hour in 10 percent formaldehyde, a procedure that would inactivate essentially any conventional biological contaminant, brought that figure down by a factor of about 30. The material stayed infectious.

The European guideline reflects that finding in its own cleaning section. It reports that after exposure to high titre preparations, detectable infectivity can remain bound to the surface of stainless steel, and that removal of all adsorbed protein using 1 molar sodium hydroxide, or chlorine releasing disinfectants at around 20,000 parts per million chlorine for one hour, has been considered an acceptable approach where exposed equipment cannot be replaced. Where the highest infectivity category of materials is used in manufacture, dedicated equipment shall be used unless otherwise justified. Those are not the cleaning parameters of a normal peptide plant changeover, and they are the reason the framework prefers avoidance of animal-derived inputs over reliance on cleaning validation. The general problem of what a shared line can carry between products is examined in our piece on the impurity a COA purity number cannot see.

Set this against what a purity method actually measures. A truncation sequence, a deletion, an oxidised methionine and a racemised residue all have retention times. They separate, they integrate, and they appear as a percentage. An infectious protein particle introduced through a raw material has no chromophore at 214 nanometres worth speaking of, no meaningful mass fraction, and no reason to resolve from anything. A purity result of 99 percent by area normalisation says nothing about it, and a purity result of 95 percent says nothing about it either. The number is orthogonal to the question.

Geography is part of the specification, and Canadian shipping origin does not carry it

Because sourcing carries the risk, the country of origin of the source animal becomes a specification parameter in its own right. The guideline classifies countries by geographical risk and applies different rules to material from each category, including age limits on cattle from controlled risk countries that fall away for animals from negligible risk countries. This is one of the few places in pharmaceutical quality where a passport is part of the specification.

Canada sits in the most favourable category. The World Organisation for Animal Health recognised Canada as a country of negligible risk on 27 May 2021, following an application submitted in July 2020 and a preceding period of controlled risk status held since May 2007. For a Canadian research buyer that is a genuinely useful fact, but it is useful about Canadian cattle, not about a vial that shipped from a Canadian address. A peptide synthesised abroad, from protected amino acids manufactured somewhere else again, then labelled and dispatched in Canada, inherits the geographical risk profile of wherever its raw materials were sourced. Canadian shipping origin is a logistics attribute. Raw material provenance is a quality attribute. Conflating the two is one of the easier mistakes to make when reading marketing copy in this category.

It also means that a change of raw material supplier is a quality event even when the finished peptide certificate looks identical across lots. A new protected amino acid vendor can shift the country of origin of the underlying material without moving the purity number by a tenth of a percent. That is precisely the class of change that formal change notification exists to surface, discussed further in our review of supplier change control and quality agreements.

What a research buyer can actually ask for

The productive question is narrower than it first appears, because most modern protected amino acids are produced by fermentation or by wholly synthetic routes, and most peptide synthesis reagents have no animal input at all. So the request is not for a risk dossier. It is for a written statement of what is true.

Ask whether the raw materials used in synthesis are of non-animal origin, and ask for that in writing with the materials it covers named. A statement that says the product is free of materials of animal origin without saying which inputs were assessed is a slogan. Ask whether the protected amino acid supplier holds a Certificate of Suitability issued by the European Directorate for the Quality of Medicines and HealthCare, or supplies a declaration referencing EMEA/410/01 revision 3 or European Pharmacopoeia 5.2.8. Ask whether that declaration is tied to the lot supplied or is a generic corporate letter reissued unchanged for years. The same reasoning applies to allergen declarations, which sit in the same documentary blind spot for the same reason: they are statements about inputs, and the finished analysis does not test for them.

An honest supplier will often answer that it cannot produce this file, because it purchases finished peptide rather than performing the synthesis, and the declarations were never requested from the tier above. That answer is more informative than a confident one, and it tells a researcher exactly where the documentary chain ends. Our published batch certificates and what they do and do not cover are set out on the certificates of analysis page.

Limitations and open questions

Nothing here argues that the residual risk attached to a synthetic research peptide is high. On current sourcing practice it is very likely low, and the epidemiology has moved a long way since the peak of the epidemic. The argument is narrower and, for anyone reading certificates, more useful: the certificate is silent on this question, and silence is not the same as a negative result. A researcher who infers raw material provenance from a purity number has inferred something the measurement cannot support.

Three limitations are worth stating plainly. First, the European framework governs medicinal products, and research chemicals sit outside its scope entirely, so no regulator compels a research peptide supplier to hold any of these records. Second, animal-derived inputs are not confined to the amino acids. Stearates used as processing aids, glycerol and fatty acids derived from tallow, certain filter aids and some elastomeric closure components have all had animal origin routes historically, and a declaration covering only the amino acids does not cover them. Third, downstream exposure belongs to the laboratory rather than the supplier. Foetal bovine serum, porcine trypsin and animal-derived growth supplements used in a cell assay introduce their own provenance questions that no peptide certificate was ever going to answer.

The open question is whether any part of this documentation will migrate down to the research supply tier voluntarily. It has no regulatory driver, it costs money to collect, and almost no buyer currently asks. That combination usually means it does not happen until a buyer starts asking.

Research use statement

All materials discussed on this page are laboratory reagents. For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.